Ann: Re-instatement to Official Quotation Imminent, page-21

First 21 Last

Share
Profile

Follow
DiscoWarrior

2,261 Posts.

388

16/05/24

21:18

Post #: 73866558
Share

Originally posted by jackherb: ↑

I'm really sorry Bullrush but IBX's 2 bob trial (pardon the Bob pun) was useless in design (which 100% correlates to the board) and was frankly disappointing in more ways than one.
What's the plan going forward when results show that 38.4% of patients in this 'trial' had to be discarded because the images were not interpretable.
How about we don't include those ones - yer right.
You have to show that you are 'Best in Class' to warrant serious respect in this game and this board (what's currently left of it) know that.
Their confidence in the potential of success was and is zero just like their own personal investment in the stock.
I hope you enjoy helping to pay their wages.
You previously mentioned Clarity (CU6) and their huge capital raise. It was done and dusted in a day. They asked for $120 M and were flooded with $240 M but obviously only took what they needed for later phased trials. Why is it their share price is on a trajectory ? Because their diagnostic and theranostic results thus far, are proving to be far superior to current Best in Class practices.
A side note for you, compare (read thoroughly) the scientific designs of IBX's 2 bob trial (and how long did that take again) to CU6's. Chalk and cheese.
Good management is essential in the biotech arena.
Good luck.

Expand

Finally some realism. Thx

IBX Price at posting: 7.4¢ Sentiment: None Disclosure: Not Held
1 Upvote

0 Great analysis

Reply

Top Stories

OJC

SPC to merge with Original Juice Co and Nature One Dairy

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

COB

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

There are more pages in this discussion • 25 more messages in this thread...

First 21 Last

Add IBX (ASX) to my watchlist

(20min delay)
Last 4.6¢		Change -0.008(14.8%)		Mkt cap ! $1.639M

Open	High	Low	Value	Volume
5.6¢	5.6¢	4.6¢	$53.84K	1.056M

Buyers (Bids)

No.	Vol.	Price($)
1	20496	4.6¢

Sellers (Offers)

Price($)	Vol.	No.
4.8¢	1016	1

View Market Depth

No.	Vol.	Price($)
1	56000	0.045
1	87000	0.042
1	12200	0.041
3	41977	0.040
1	13000	0.039

Price($)	Vol.	No.
0.048	1016	1
0.049	10000	1
0.052	155207	1
0.053	83715	1
0.054	50000	1

Last trade - 15.51pm 02/10/2024 (20 minute delay)

IBX (ASX) Chart

Ann: Re-instatement to Official Quotation Imminent, page-21

SPC to merge with Original Juice Co and Nature One Dairy

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Re-instatement to Official Quotation Imminent, page-21

Top Stories

SPC to merge with Original Juice Co and Nature One Dairy

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News